S1823: A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

About this Study

Studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers.

Sponsor Protocol ID:S1823
IRB Number:2021-0581
Actively Enrolling
Interventional
Observational/Not Applicable
July 12, 2022
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Must have a new diagnosis of a germ cell tumor, confirmed pathologically or serologically
  • If surgery is planned, male patients with clinical stage I testicular cancer must have orchiectomy completed within 42 days prior to registration
  • Must register within 42 days after diagnosis and prior to start of management plan or treatment for the disease
  • Must agree to submit required specimens for defined translational medicine studies

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials